Aethlon Medical Reports on Landmark Human Study

Aethlon Medical, Inc., (OTCBB:AEMD) disclosed today that it has

published a paper entitled: “A Clinical Report on the Safety

of the Aethlon HemopurifierTM.” The

report details the landmark use of the HemopurifierTM

in a human infectious disease study conducted at the Apollo Hospital in

Delhi, India. The HemopurifierTM is a

first-in-class device designed to fill the void in treating drug and

vaccine resistant pathogens. The report is available online at: www.aethlonmedical.com/pdfs/ApolloHospitalSafetyStudy.pdf

“The Apollo study advances our mission to establish the industry for

medical devices to treat infectious disease,” stated Aethlon Chairman &

CEO James A. Joyce. “The study also triggers our regulatory endeavors in

the United States and sets the stage for us to expand efforts to treat

multiple disease targets in India,” concluded Joyce.

The report details clinical data collected during a study sponsored by

Aethlon Medical to demonstrate the safety of the HemopurifierTM

in health-compromised humans. The study also provided an opportunity to

observe the capture of Hepatitis-C virus (“HCV”) from HCV infected end

stage renal disease (“ESRD”) study subjects undergoing intermittent

dialysis. In tested cartridges, up to 52% of pre-treatment viral load

was captured during a single treatment with the HemopurifierTM.

Twenty-four Hemopurifier cartridges were tested on four study subjects

suffering from ESRD and HCV infection. Each cartridge purified the blood

of study subjects for up to four hours in six sequential treatments per

patient every two to three days. All enrolled patients completed the

entire treatment regimen.

About Aethlon Medical

Aethlon Medical is developing the first-in-class medical device to treat

infectious disease. The device, known as the HemopurifierTM,

is a broad-spectrum treatment countermeasure against drug and vaccine

resistant bioweapons, naturally evolving pandemic threats such as H5N1

Avian Flu, and chronic infectious disease targets, including Hepatitis-C

(HCV) and the Human Immunodeficiency Virus (HIV). Global researcher

Frost & Sullivan recently awarded the HemopurifierTM

the 2006 Technology Innovation Award

for its advances in the field of biodefense. Aethlon has also initiated

research on a second generation HemopurifierTM

that targets the capture of growth factors inherent in the spread of

Cancer. More information on Aethlon Medical and the HemopurifierTM

technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve

risks and uncertainties. Such forward-looking statements involve

assumptions, known and unknown risks, uncertainties and other factors

which may cause the actual results, performance or achievements of

Aethlon Medical, Inc. to be materially different from any future

results, performance or achievements expressed or implied by the

forward-looking statements. Such potential risks and

uncertainties include, without limitation, the Company’s

ability to raise capital when needed, the Company’s

ability to complete the development of its planned products, the ability

of the Company to obtain FDA and other regulatory approvals permitting

the sale of its products, the Company’s

ability to manufacture its products and provide its services, the impact

of government regulations, patent protection on the Company’s

proprietary technology, product liability exposure, uncertainty of

market acceptance, competition, technological change and other risk

factors. In such instances, actual results could differ materially as a

result of a variety of factors, including the risks associated with the

effect of changing economic conditions and other risk factors detailed

in the Company’s Securities and Exchange

Commission filings.